The Therapeutic Effects of Forced Aerobic Exercise in Multiple Sclerosis

Sponsor
The Cleveland Clinic (Other)
Overall Status
Recruiting
CT.gov ID
NCT04906057
Collaborator
(none)
20
2
2
28.8
10
0.3

Study Details

Study Description

Brief Summary

This project will investigate the feasibility and initial efficacy of two aerobic exercise training approaches, forced and voluntary, to improve motor function in persons with multiple sclerosis (MS). We hypothesize that intensive aerobic exercise training elicits a neurorepairative and neurorestorative response on the central nervous system, which may improve motor function as it relates to gait and mobility. Should aerobic cycling, forced or voluntary, improve gait and functional mobility in persons with MS, it would serve as a new model to restoring function, rather than current models that focus on compensation.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Forced Aerobic Exercise (FE)
  • Behavioral: Voluntary Aerobic Exercise (VE)
N/A

Detailed Description

Multiple sclerosis (MS) is a chronic inflammatory and neurodegenerative disease of the central nervous system characterized by progressive loss of motor function, cognitive function, in addition to symptoms of fatigue and depression. These motor and non-motor symptoms negatively affect the individuals' walking ability, functional mobility, quality of life, ability to maintain gainful employment, and social engagement. Identifying rehabilitation approaches that may delay disease progression or restore lost neurologic function would have considerable impact in the field. The goal of this project is to investigate the feasibility and initial efficacy of forced or voluntary aerobic exercise training to improve gait, functional mobility, fatigue and quality of life in persons with multiple sclerosis (PwMS). Current rehabilitative approaches for PwMS focus on training compensatory strategies rather than restoring neurological function. Substantial evidence indicates that aerobic exercise (AE) training has the potential to enhance neurological function by restoring and repairing damaged cells, leading to improvements in gait, balance, and cognitive function in PwMS. Despite evidence of the potential disease-modifying properties of AE, numerous physical, behavioral, and logistical barriers prevent PwMS from achieving and maintaining AE of sufficient intensity and duration to capitalize on the neurophysiologic benefits of training. Forced exercise (FE) is a novel approach to AE training that has been successfully applied to individuals with Parkinson's disease and stroke, in which the voluntary efforts of the individual are augmented, allowing for disease-altering effects of intensive exercise training. During FE, pedaling cadence on a stationary cycle is augmented by a motor to assist, but not replace, the voluntary efforts of the individual. It is hypothesized that PwMS cannot sustain high rates of voluntary exercise necessary to elicit neural repair; therefore, FE is necessary to overcome physical, behavioral and logistical barriers to enhance neuroplasticity to improve gait, QOL, and the ability to participate in life activities. Positive results from our FE trials in Parkinson's disease and stroke have guided us in designing the scientific methodology for the proposed trial in PwMS. Twenty adults with relapsing-remitting MS and mild to moderate gait impairment will be randomized to undergo 1) FE or 2) voluntary aerobic exercise (VE). Both groups will attend 2X/week for 12 weeks. Exercise variables will be collected for each session as a measure of feasibility to determine how PwMS respond to each exercise approach. Clinical, biomechanical, and self-reported outcomes will be gathered prior to, after, and 4-weeks after the intervention to determine the effects of both modes of exercise on spatiotemporal and kinematic characteristics of gait, functional mobility, balance, fatigue, physical activity levels, and quality of life. Should our findings confirm our hypothesis that intensive exercise training can have disease-altering effects, a new direction for MS rehabilitation approaches would ensue, empowering PwMS to take control of their disease to improve function and reduce disability.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
20 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
rater-blind, prospective randomized trialrater-blind, prospective randomized trial
Masking:
Single (Outcomes Assessor)
Masking Description:
Group allocation will be concealed to the individual obtaining all outcomes of interest
Primary Purpose:
Treatment
Official Title:
The Therapeutic Effects of Forced Aerobic Exercise in Multiple Sclerosis
Actual Study Start Date :
Jul 6, 2021
Anticipated Primary Completion Date :
Dec 1, 2023
Anticipated Study Completion Date :
Dec 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Forced Aerobic Exercise (FE)

The FE group (N=10) will complete 45 minutes of FE on the custom-engineered cycle designed to augment pedaling rate to greater than 70 revolutions per minute (RPM's). The VE group (N=10) will exercise on an identical semi-recumbent cycle ergometer at their self-selected cadence without assistance.

Behavioral: Forced Aerobic Exercise (FE)
High-rate aerobic exercise on a semi-recumbent custom-designed stationary cycle ergometer

Active Comparator: Voluntary Aerobic Exercise (VE)

The VE group (N=10) will exercise on an identical semi-recumbent cycle ergometer for 45 minutes at their self-selected cadence without assistance.

Behavioral: Voluntary Aerobic Exercise (VE)
Voluntary-rate aerobic exercise on a semi-recumbent stationary cycle ergometer

Outcome Measures

Primary Outcome Measures

  1. Exercise variables [collected during each exercise session (twice per week for 12 weeks)]

    Exercise cadence, power, and aerobic intensity achieved during the 35-minute main exercise set

  2. Biomechanical Gait Assessment [Week 0 (baseline), Week 13 (post exercise sessions)]

    Spatio-temporal and kinematic parameters of gait will be obtained using 3-D motion capture and an instrumented walkway. The following biomechanical outcomes will be calculated: 1) spatio-temporal: velocity; cadence, step length, percentage of gait cycle spent in swing and stance phase, single and double limb support time and percentage; 2) Kinematic: hip and knee flexion and extension; ankle dorsi- and plantar-flexion; pelvic obliquity, rotation and tilt.

  3. Instrumented Timed Up and Go (TUG) [Week 0 (baseline), Week 13 (post exercise sessions)]

    The TUG will be administered while participants wear an iPad to collect biomechanical data during the clinical test

  4. Six Minute Walk Test [Week 0 (baseline), Week 13 (post exercise sessions)]

    The distance walked over 6 minutes is measured on an oval walking track

  5. PROMIS-29 [Week 0 (baseline), Week 13 (post exercise sessions)]

    self-reported measure of quality of life

  6. Multiple Sclerosis Performance Test [Week 0 (baseline), Week 13 (post exercise sessions)]

    Assessment examining cognitive and visual function for persons with MS

Secondary Outcome Measures

  1. Modified Fatigue Impact Scale [Week 0 (baseline), Week 13 (post exercise sessions)]

    self-reported measure of fatigue

  2. To investigate the role of Klotho in promoting neuroprotection. [Week 1 (exercise session 1), Week 12 (exercise session 24)]

    Laboratory Assessment: Blood draws will be conducted at 4 different points in time to determine the acute and long-term change in serum Klotho; at week one session one, pre- and post-exercise, and at the last session12-week exercise intervention, pre- and post-exercise.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 75 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Confirmed diagnosis of RRMS with Expanded Disability Status Scale (EDSS) score between 1.5 and 6.5,

  2. 18-75 years of age,

  3. Deemed minimal risk for cardiovascular event using American College of Sports Medicine Exercise Pre-participation Criteria

Exclusion Criteria:
  1. hospitalization for myocardial infarction, heart failure or heart surgery within 3 months,

  2. serious cardiac arrhythmia,

  3. hypertrophic cardiomyopathy,

  4. severe aortic stenosis,

  5. pulmonary embolus,

  6. significant contractures,

  7. dysphagia resulting in inability to sufficiently hydrate, and

  8. other contraindication to exercise.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Cleveland Clinic Main Campus Cleveland Ohio United States 44195
2 Cleveland Clinic Cleveland Ohio United States 44195

Sponsors and Collaborators

  • The Cleveland Clinic

Investigators

  • Principal Investigator: Susan M Linder, DPT, The Cleveland Clinic

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Susan Linder, Assistant Staff, Physical Medicine and Rehabilitation, The Cleveland Clinic
ClinicalTrials.gov Identifier:
NCT04906057
Other Study ID Numbers:
  • 19-1003
First Posted:
May 28, 2021
Last Update Posted:
Aug 11, 2021
Last Verified:
Aug 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Susan Linder, Assistant Staff, Physical Medicine and Rehabilitation, The Cleveland Clinic
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 11, 2021